cell therapy Archives

Conceptual illustration of robotic arms automating drug manufacturing, with a giant glass vessel pouring into bioreactors against the San Francisco skyline.

Multiply Labs Raises $75 Million as Physical AI Takes Aim at Biotech’s Manufacturing Bottleneck -( $AZN $KYTX $LEGN $NVS $TER )

by John F. Heerdink, Jr. October 11, 2026 626Views 0Likes

Backed by AstraZeneca and Teradyne, the robotics company is betting that the next breakthrough in medicine will need a breakthrough on the factory floor. Artificial intelligence can help design a promising medicine. It cannot deliver a dose by admiring its own calculations.…

Alt Text: Illustration of the Nobel Prize in Medicine lighting a new bull market for brain science, featuring a glowing brain, neural connections, a rising stock-market chart and a charging digital bull above a city skyline as researchers look on.

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

by John F. Heerdink, Jr. October 5, 2026 343Views 0Likes

The 2026 Nobel Prize in Physiology or Medicine has put optogenetics, the science of using light to control precisely selected nerve cells, squarely in the global spotlight. For many, the award is more than a ceremonial victory lap for academic neuroscience:…

Iovance Biotherapeutics revenue guidance display in a modern trading-floor setting, highlighting rising Amtagvi demand, a Goldman Sachs Buy rating, and NASDAQ market screens.

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

by John F. Heerdink, Jr. September 30, 2026 436Views 0Likes

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) delivered the sort of update growth investors prefer: higher guidance, record revenue, expanding treatment access, and a more visible route toward operating leverage. Shares climbed sharply after the company lifted its 2026 revenue outlook, suggesting Wall Street is…

Daily stock market summary graphic for Tuesday, September 29, 2026, showing a declining market-index chart, the message “Stocks Finish Lower,” and an elevated bond-yield gauge noting that high Treasury yields added pressure to equities.

Daily Stock Market Summary ( Tuesday, September 29, 2026): Stocks Finish Lower As Yields Stay Elevated -( $AMZN $CCL $DOCS $EPRX $F $FICO $IOVA $META $MODD $SER $SHOP $TGT $WMT $YSG )

by John F. Heerdink, Jr. September 29, 2026 104220Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Repligen’s $1.5B BioLife Acquisition Fits a Bigger Shift in Biotech M&A -( $BLFS $JPM $RGEN )

by John F. Heerdink, Jr. July 22, 2026 270Views 0Likes

Repligen’s (REGN) $1.5 billion purchase of BioLife Solutions (BLFS) lands in the middle of a biotech M&A market that is getting bigger, faster, and a bit more strategic than the old “buy the science and hope for the best” model. The deal…

Tag: cell therapy

Multiply Labs Raises $75 Million as Physical AI Takes Aim at Biotech’s Manufacturing Bottleneck -( $AZN $KYTX $LEGN $NVS $TER )

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

Daily Stock Market Summary ( Tuesday, September 29, 2026): Stocks Finish Lower As Yields Stay Elevated -( $AMZN $CCL $DOCS $EPRX $F $FICO $IOVA $META $MODD $SER $SHOP $TGT $WMT $YSG )

Repligen’s $1.5B BioLife Acquisition Fits a Bigger Shift in Biotech M&A -( $BLFS $JPM $RGEN )

Your Guide To Staying Informed In The Markets